# ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD

> **NCT00801684** · PHASE2 · COMPLETED · sponsor: **Alkermes, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** Placebo
- **DRUG:** TrIP-2D
- **DRUG:** TrIP-2SS
- **DRUG:** TrIP-2D
- **DRUG:** TrIP-2SS + Foradil

## Key facts

- **NCT ID:** NCT00801684
- **Lead sponsor:** Alkermes, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2009-04
- **Final completion:** 2009-07
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2011-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00801684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00801684, "ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00801684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*